Jennerex, Inc. Completes $21.6 Million Private Placement
5/23/2013 7:30:07 AM
More...
|
Jennerex, Inc. Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
5/21/2013 11:16:33 AM
More...
|
Jennerex, Inc. Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-Cancer Immunity in Patients With Diverse Tumor Types
5/16/2013 12:10:12 PM
More...
|
Jennerex, Inc. Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
5/9/2013 11:03:16 AM
More...
|
Jennerex, Inc. Announces Presentation of Data Demonstrating Pexa-Vec's Vascular Targeting Mechanism
4/9/2013 11:41:49 AM
More...
|
Liver Cancer Survival Time Tripled by Virus, Jennerex, Inc. Reveals
2/13/2013 7:22:52 AM
More...
|
Jennerex, Inc. Announces Nature Medicine Publication Highlighting Randomized Overall Survival Benefit of Lead Product Candidate, Pexa-Vec (JX-594) in Patients With Advanced Hepatocellular Carcinoma (HCC)
2/11/2013 9:26:19 AM
More...
|
Jennerex, Inc. Announces Cancer Research Publication Demonstrating Vascular Targeting Mechanism of Action of Lead Product Candidate, Pexa-Vec (JX-594)
2/11/2013 8:58:52 AM
More...
|
Genetically Engineered Virus Kills Liver Cancer, Jennerex, Inc. Reveals
2/11/2013 7:35:15 AM
More...
|
Jennerex, Inc.'s Drug Candidate, JX-929, Named as One of the Top 10 Oncology Projects to Watch
11/28/2012 9:15:45 AM
More...
|
|